Subscribe To
Nuvalent to present new preclinical data on ros1-selective inhibitor nvl-520 and alk-selective inhibitor nvl-655 at aacr annual meeting 2022
CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL) a biotechnology company creating ...
March 8, 2022, 5:38 pm
On the front lines of investor recession concerns
The Fed is set to conclude its two-day meeting on its policies to address the current inflationary rate and other economic pressures seen recently. In...
January 26, 2022, 1:54 pm
On the front lines of investor recession concerns
The Fed is set to conclude its two-day meeting on its policies to address the current inflationary rate and other economic pressures seen recently. In...
January 26, 2022, 1:54 pm
On the front lines of investor recession concerns
The Fed is set to conclude its two-day meeting on its policies to address the current inflationary rate and other economic pressures seen recently. In...
January 26, 2022, 1:54 pm
New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc
CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating ...
October 7, 2021, 9:21 am
New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc
CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating ...
October 7, 2021, 9:21 am
New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc
CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating ...
October 7, 2021, 9:21 am